Literature DB >> 201566

Alteration of host defense mechanisms by murine cytomegalovirus infection.

D K Kelsey, G A Olsen, J C Overall, L A Glasgow.   

Abstract

An animal model of a sublethal infection, utilizing murine cytomegalovirus (MCMV), was developed to determine whether immunological factors could contribute to the establishment of a persistent viral infection. Adult female C3H mice inoculated intraperitoneally with 10(5) plaque-forming units of MCMV developed splenomegaly 5 to 12 days after infection. Virus replicated to peak titers (10(3) to 10(6) plaque-forming units per g of tissue) in liver, spleen, lung, kidney, and salivary gland tissue during the acute phase of the infection (3 to 12 days); it then decreased to undetectable levels in all tissues except salivary gland. Serum interferon was detected as early as 12 h after infection, peaked at 36 h (1,093 U/ml), and was undetectable by 4 days after infection. MCMV-infected animals were hyporeactive to interferon induction with New castle disease virus on days 5 to 9 of the infection. Splenic lymphocyte reactivity to phytohemagglutinin and lipopolysaccharide was normal early during the course of the infection, was suppressed during the acute phase of the infection, and had returned to normal by day 18. These data indicate that several parameters of host defense are transiently suppressed during the course of a MCMV infection. The capacity of cytomegaloviruses to alter host resistance may be one factor that contributes to the establishment of a persistent infection.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 201566      PMCID: PMC421299          DOI: 10.1128/iai.18.3.754-760.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Lactic dehydrogenase activity in blood.

Authors:  F WROBLEWSKI; J S LADUE
Journal:  Proc Soc Exp Biol Med       Date:  1955-10

2.  Maternal cytomegalovirus excretion and perinatal infection.

Authors:  D W Reynolds; S Stagno; T S Hosty; M Tiller; C A Alford
Journal:  N Engl J Med       Date:  1973-07-05       Impact factor: 91.245

3.  Cytomegalovirus-induced immune suppression. II. Cell-mediated immunity.

Authors:  R J Howard; J Miller; J S Najarian
Journal:  Clin Exp Immunol       Date:  1974-09       Impact factor: 4.330

4.  Latent cytomegalovirus infection in blood donors.

Authors:  P Diosi; E Moldovan; N Tomescu
Journal:  Br Med J       Date:  1969-12-13

5.  Tilorone hydrochloride: an oral interferon-inducing agent.

Authors:  D A Stringfellow; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1972-08       Impact factor: 5.191

6.  Suppressed response to interferon inducation in mice infected with encephalomyocarditis virus, Semliki forest virus, influenza A2 virus, Herpesvirus hominis type 2, or murine cytomegalovirus.

Authors:  D A Stringfellow; E R Kern; D K Kelsey; L A Glasgow
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

7.  Hyporeactivity due to infection: recognition of a transferable hyporeactive factor in the serum of encephalomyocarditis virus-infected mice.

Authors:  D A Stringfellow; L A Glasgow
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

8.  Mouse cytomegalovirus: isolation from spleen and lymph nodes of chronically infected mice.

Authors:  D Henson; A J Strano; M Slotnik; C Goodheart
Journal:  Proc Soc Exp Biol Med       Date:  1972-07

9.  Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses.

Authors:  I Gresser; M G Tovey; C Maury; M T Bandu
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

10.  Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection.

Authors:  I Gresser; M G Tovey; M E Bandu; C Maury; D Brouty-Boyé
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  21 in total

Review 1.  The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections.

Authors:  J B Hudson
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

Review 2.  Animal cytomegaloviruses.

Authors:  J Staczek
Journal:  Microbiol Rev       Date:  1990-09

Review 3.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

4.  Comparison of serological tests for the detection of antibody to natural and experimental murine cytomegalovirus.

Authors:  G Lussier; D Guénette; J P Descôteaux
Journal:  Can J Vet Res       Date:  1987-04       Impact factor: 1.310

5.  Restoration of immunological responses by THF, a thymic hormone, in mice infected with murine cytomegalovirus (MCMV).

Authors:  E Katorza; M Pecht; R N Apte; D Benharroch; Y Burstein; N Trainin; B Rager-Zisman
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

6.  Murine cytomegalovirus infection in the spleen and its relationship to immunosuppression.

Authors:  L Loh; J B Hudson
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

7.  Replication of murine cytomegalovirus in lung macrophages: effect of phagocytosis of bacteria.

Authors:  J D Shanley; E L Pesanti
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

8.  Accelerated rejection of murine cardiac allografts by murine cytomegalovirus-infected recipients. Lack of haplotype specificity.

Authors:  J F Carlquist; J Shelby; Y L Shao; J H Greenwood; M E Hammond; J L Anderson
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  Neutrophil response and function during acute cytomegalovirus infection in guinea pigs.

Authors:  E L Yourtee; F J Bia; B P Griffith; R K Root
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

10.  Murine cytomegalovirus-induced immunosuppression.

Authors:  L Loh; J B Hudson
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.